106%+ returns, 97% win rate: A fresh list of AI-picked stock is out NOW
ORLANDO - Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, has announced an exclusive partnership with Kindeva Drug Delivery to develop Aversa™ Fentanyl, a potential abuse-deterrent fentanyl patch. The collaboration is grounded in a revised agreement that commits both parties to share development costs and includes milestone payments. The company, currently valued at $79 million, has demonstrated strong market performance with a 174% return over the past year. According to InvestingPro analysis, the stock is trading near its Fair Value, with several positive indicators available to subscribers.
The Aversa™ Fentanyl patch is designed to incorporate Nutriband’s proprietary abuse-deterrent technology, which uses taste aversion to discourage misuse and accidental exposure of opioid and stimulant patches. The technology is patented in 46 countries, including major markets like the United States, Europe, and Japan.
This partnership aims to address the significant issue of opioid abuse by creating a safer transdermal delivery system for fentanyl, which remains an important medication for patients with severe pain. According to a market analysis report by Health Advances, Aversa Fentanyl could achieve peak annual sales in the U.S. ranging from $80 million to $200 million.
The success of this venture, however, hinges on various factors including the development of the product, securing patent protection, obtaining necessary financing and regulatory approvals, and ultimately, the ability to market the patch effectively.
Nutriband’s focus on enhancing the safety profile of transdermal drugs susceptible to abuse aligns with Kindeva’s expertise in drug-device combination products, potentially positioning Aversa Fentanyl as the first abuse-deterrent opioid patch on the market.
This news is based on a press release statement and reflects the companies’ current expectations and projections about future events. The realization of these expectations is subject to risks and uncertainties that could cause actual results to differ materially.
In other recent news, NutriBand Inc. has made significant strides in expanding its intellectual property portfolio. The Nevada-based pharmaceutical company has secured a patent for its Aversa™ abuse deterrent technology, a major development that could enhance its position within the orthopedic, prosthetic, and surgical appliances and supplies sector. The United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the patent, indicating that the patent will be granted once administrative procedures are completed.
In other related news, NutriBand shareholders have approved key proposals at their Annual Meeting, including the election of directors and the approval of the company’s amended stock option plan. All seven director nominees were elected to serve one-year terms on the company’s board.
In the realm of financial analysis, Noble Capital initiated coverage on NutriBand with an Outperform rating and a price target of $13.00. This rating is based on the firm’s optimism about NutriBand’s upcoming Phase 1 clinical trial and its potential to file a New Drug Application using the 505(b)(2) regulatory pathway in the second half of 2025. These recent developments highlight the ongoing progress and strategic direction of NutriBand.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.